Results 31 to 40 of about 5,304 (170)
Budget impact analysis of acalabrutinib plus venetoclax in chronic lymphocytic leukemia
Objective: To evaluate the budget impact of a fixed-duration combination (FC) “acalabrutinib + venetoclax” regimen for treatmentnaive adults with chronic lymphocytic leukemia (CLL), unmutated IGHV, and absence of del(17p) or mutations in TP53 in the ...
S. V. Nedogoda +4 more
doaj +1 more source
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib [PDF]
Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations.
Benrashid, Samon +17 more
core +2 more sources
Figure 1. Structures of acalabrutinib and ibrutinib. A. Chemical structure of acalabrutinib. B. Chemical structure of ibrutinib.
Mary Ayres (356964) +6 more
core +1 more source
Bruton tyrosine kinase (BTK) inhibition is an effective therapy for many B-cell malignancies. Acalabrutinib is a next-generation, potent, highly selective, covalent BTK inhibitor.
Owen, Roger G +22 more
core +2 more sources
Krista Isaac,1 Anthony R Mato2 1Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, VA, USA; 2Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence: Krista ...
Isaac K, Mato AR
doaj
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median duration of survival of approximately 14 months after diagnosis. High resistance to chemotherapy remains a major problem.
Yu-Kai Su +8 more
doaj +1 more source
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension.
Sunnia T. Chen +17 more
doaj +1 more source
Aims The phase 3 ECHO trial demonstrated superior progression‐free survival (PFS) with acalabrutinib plus bendamustine‐rituximab (BR) versus placebo plus BR in treatment‐naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP‐5862 (active metabolite) when administered with BR and ...
Damilola Olabode +7 more
wiley +1 more source
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou +4 more
wiley +1 more source
Video abstract for our matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic ...
Adam S. Kittai (15088179) +8 more
core +1 more source

